By Fineline Cube 
On August 21, 2025, Bio-Thera Solutions, Ltd. (SHA: 688177) announced a license and commercialization agreement with STADA Arzneimittel AG (STADA). The deal grants STADA exclusive rights to commercialize Bio-Thera’s BAT1806 (tocilizumab) in the EU, Switzerland, the UK, other European regions, and selected MENA and CIS countries.
Agreement Details
Bio-Thera will receive up to EUR 136 million, including an EUR 8.5 million upfront payment and EUR 127.5 million in potential milestone payments. Additionally, the company will earn a double-digit percentage of net sales as revenue sharing.
BAT1806: A Biosimilar Innovation
BAT1806 is a biosimilar developed by Bio-Thera, targeting the interleukin-6 receptor (IL-6R) to inhibit signal transduction. It has received marketing approval from China NMPA, U.S. FDA, and European EMA, with the U.S. trade name TOFIDENCE.-Fineline Info & Tech